| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kgato P Selwe, Ambar S A Shaikh, Kelechi O Uleanya, Caroline E H Dessen. Fragmentation and Isomerization Pathways of Natural and Synthetic Cannabinoids Studied via Higher Collisional Energy Dissociation Profiles. Molecules (Basel, Switzerland). vol 30. issue 3. 2025-02-13. PMID:39942819. |
in this work, we perform higher collisional dissociation (hcd) mass spectrometric measurements on an orbitrap fusion tribrid mass spectrometer to measure the collision-energy-dependent molecular fragmentation pathways of a group of key cannabinoids and their metabolites (cannabidiol, Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol, cannabidiolic acid, tetrahydrocannabinolic acid), along with two synthetic cannabinoids (jwh-018 and mdmb-fubinaca). |
2025-02-13 |
2025-02-15 |
human |
| Samad Nazemi, Atena Adel-Rastkhiz, Marzieh Kafami, Bahareh Amin, Mohammad Mohammad-Zadeh, Mohammad-Shafi Mojadad. The cannabinoid CB2 receptor mediates the analgesic effects of Cannabis sativa extract in a rat model of neuropathic pain. Behavioural brain research. 2025-02-13. PMID:39947333. |
the cannabinoid cb2 receptor mediates the analgesic effects of cannabis sativa extract in a rat model of neuropathic pain. |
2025-02-13 |
2025-02-16 |
rat |
| Bertrand Redonnet, Filiz Eren, Guillaume Avenin, Maria Melchior, Murielle Mary-Kraus. Efficacy of cannabidiol alone or in combination with Δ-9-tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence. Addiction (Abingdon, England). 2025-02-13. PMID:39947878. |
cannabidiol (cbd) is being investigated as a potential therapeutic target due to its pharmacological properties and mode of action in the endocannabinoid system. |
2025-02-13 |
2025-02-16 |
Not clear |
| Helena M Teixeir. Phytocanabinoids and synthetic cannabinoids: from recreational consumption to potential therapeutic use - a review. Frontiers in toxicology. vol 6. 2025-02-12. PMID:39936019. |
the word "cannabinoid" refers to any chemical substance, regardless of structure or origin, that binds to the body's cannabinoid receptors and that has effects similar to those produced by the cannabis plant. |
2025-02-12 |
2025-02-14 |
Not clear |
| Travis T Denton, Gregory T Carter, Megan Goddard, Jeremy Weiss, Douglas L Weeks, Patrick Weydt, Ethan B Russo, Michael D Weis. Amyotrophic Lateral Sclerosis, the Endocannabinoid System, and Exogenous Cannabinoids: Current State and Clinical Implications. Muscle & nerve. 2025-02-12. PMID:39936266. |
cannabinoids, including delta-9-tetrahydrocannabinol (thc), cannabidiol (cbd), cannabigerol (cbg), and others found in cannabis, and cannabis extracts (ces), appear to have activity in these pathogenic pathways, which have led to increasing interest in cannabinoids as therapeutic agents for als. |
2025-02-12 |
2025-02-14 |
Not clear |
| Isabel R Aks, Herry Patel, William E Pelham, Marilyn A Huestis, Natasha E Wad. Cannabinoids in hair and their prospective association with mental and physical health outcomes in adolescents. Neurotoxicology and teratology. 2025-02-10. PMID:39929394. |
cannabinoids within the cannabis plant (e.g., delta-9-tetrahydrocannabinol [thc], and cannabidiol [cbd]) are suggested to have a range of health implications. |
2025-02-10 |
2025-02-13 |
Not clear |
| Alwyn Henrique. Cannabinoid spoilage, metabolism and cannabidiol(CBD) conversion to Tetrahydrocannabinol(THC) mechanisms with energetic parameters. Journal of cannabis research. vol 7. issue 1. 2025-02-10. PMID:39930523. |
cannabinoid spoilage, metabolism and cannabidiol(cbd) conversion to tetrahydrocannabinol(thc) mechanisms with energetic parameters. |
2025-02-10 |
2025-02-13 |
Not clear |
| Austin T Jones, Alaa Marwan Abu Taha, Grover P Mille. The Resurgence of Synthetic Cannabinoid Receptor Agonists as Adulterants in the Era of Cannabis Legalization: Lessons from Prior Epidemics and Clinical Implications. Neuroscience and biobehavioral reviews. 2025-02-08. PMID:39922438. |
momentum towards legalization of medical and recreational cannabis drives a convergence between natural cannabinoids and their synthetic counterparts, creating new clinical challenges in a second wave of exposures. |
2025-02-08 |
2025-02-11 |
Not clear |
| Kristofer Svendsen, Amyaouch Bradaia, Maria A Gandini, Manon Defaye, Chelsea Matisz, Nasser S Abdullah, Aaron Gruber, Gerald W Zamponi, Keith A Sharkey, Christophe Altie. Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. The Journal of pharmacology and experimental therapeutics. vol 392. issue 3. 2025-02-08. PMID:39921943. |
cannabis contains over 100 cannabinoids which, unlike tetrahydrocannabinol, are biologically active compounds often without psychotropic effects (ie, nonpsychotropic cannabinoids [npcbs]). |
2025-02-08 |
2025-02-11 |
mouse |
| Kristofer Svendsen, Amyaouch Bradaia, Maria A Gandini, Manon Defaye, Chelsea Matisz, Nasser S Abdullah, Aaron Gruber, Gerald W Zamponi, Keith A Sharkey, Christophe Altie. Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. The Journal of pharmacology and experimental therapeutics. vol 392. issue 3. 2025-02-08. PMID:39921943. |
nonpsychotropic cannabinoids, such as cannabidiol, interact with ionotropic and voltage-gated ion channels. |
2025-02-08 |
2025-02-11 |
mouse |
| Kristofer Svendsen, Amyaouch Bradaia, Maria A Gandini, Manon Defaye, Chelsea Matisz, Nasser S Abdullah, Aaron Gruber, Gerald W Zamponi, Keith A Sharkey, Christophe Altie. Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis. The Journal of pharmacology and experimental therapeutics. vol 392. issue 3. 2025-02-08. PMID:39921943. |
in our study, we demonstrated that cannabidiol, cannabigerol, and a combination of nonpsychotropic cannabinoids, administered at subtherapeutic doses, effectively alleviated visceral hypersensitivity associated with inflammatory bowel disease. |
2025-02-08 |
2025-02-11 |
mouse |
| b' Magdal\\xc3\\xa9na V\\xc3\\xa1gnerov\\xc3\\xa1, David S\\xc3\\xbdkora, Al\\xc5\\xbeb\\xc4\\x9bta Neme\\xc5\\xa1kalov\\xc3\\xa1, Martin Kucha\\xc5\\x9. Challenges of cannabidiol determination in emulsified cosmetics and application of solid-phase extraction followed by HPLC-UV-MS/MS. Analytical and bioanalytical chemistry. vol 417. issue 6. 2025-02-06. PMID:39762637.' |
in this work, we present the use of an hplc-uv-ms/ms method for the quantification of five major cannabinoids (cannabidiol, cannabidiolic acid, tetrahydrocannabinol, tetrahydrocannabinolic acid, and cannabigerol) in oil-in-water cosmetic emulsions. |
2025-02-06 |
2025-02-08 |
Not clear |
| Xuanhe Fu, Zhixiong Yu, Fang Fang, Weiping Zhou, Yuxin Bai, Zhongjia Jiang, Biao Yang, Ye Sun, Xing Tian, Guangyan Li. Cannabidiol attenuates lipid metabolism and induces CB1 receptor-mediated ER stress associated apoptosis in ovarian cancer cells. Scientific reports. vol 15. issue 1. 2025-02-05. PMID:39910152. |
as the primary ingredient in exogenous cannabinoids, cannabidiol (cbd) has been confirmed to exhibit antitumor activity in preclinical studies. |
2025-02-05 |
2025-02-08 |
Not clear |
| Si-Yuan Shen, Chao Wu, Zhi-Qian Yang, Ke-Xin Wang, Zhen-Hua Shao, Wei Ya. Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery. Acta pharmacologica Sinica. 2025-02-05. PMID:39910211. |
cannabinoid receptors are the primary targets that mediate the effects of cannabis and its analogs. |
2025-02-05 |
2025-02-08 |
Not clear |
| Kevin M Gray, Rachel L Tomko, Nathaniel L Baker, Erin A McClure, Aimee L McRae-Clark, Lindsay M Squegli. N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2025-02-05. PMID:39910268. |
the n-acetylcysteine and placebo groups did not differ in proportion of negative urine cannabinoid tests (rr = 0.93, 95% ci = 0.53, 1.64; p = 0.80) or self-reported cannabis abstinence (rr = 1.02, 95% ci = 0.63, 1.65; p = 0.93) during treatment. |
2025-02-05 |
2025-02-08 |
human |
| Qianqian Gao, Muhammad Asi. CB Neurochemistry international. 2025-02-04. PMID:39904420. |
historically, cannabis has been utilized for centuries to mitigate symptoms of anxiety and depression; however, the precise role of cannabinoids in these conditions has only recently garnered extensive research attention. |
2025-02-04 |
2025-02-07 |
Not clear |
| Andriy A Gorbenko, Jules A A C Heuberger, Maria Juachon, Erica Klaassen, Michael Tagen, Joseph F Lawler, Daniel Schneeberger, Kenneth C Cundy, Linda E Klumpers, Geert J Groenevel. CB Clinical pharmacology and therapeutics. 2025-02-03. PMID:39898464. |
cb emergency department visits due to cannabinoid-induced toxicity, including acute cannabinoid intoxication (aci) have increased worldwide as more states have liberalized cannabis policy. |
2025-02-03 |
2025-02-05 |
Not clear |
| Yuxi Li, Xilin Li, Patrick Cournoyer, Supratim Choudhuri, Lei Guo, Si Che. Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells. Toxicology. 2025-02-02. PMID:39894194. |
cannabidiol (cbd), a major cannabinoid found in cannabis sativa l., has been used in the treatment of seizures associated with lennox-gastaut syndrome, dravet syndrome, and tuberous sclerosis complex. |
2025-02-02 |
2025-02-05 |
mouse |
| Savannah H M Lightfoot, Andrei S Nastase, Gabriela Costa Lenz Cesar, Catherine Hume, Renaud C Gom, G Campbell Teskey, Matthew N Hil. Acute and chronic cannabis vapor exposure produces immediate and delayed impacts on phases of fear learning in a sex specific manner. Psychopharmacology. 2025-01-31. PMID:39888377. |
cannabis and cannabinoids that act through the endogenous cannabinoid (endocannabinoid) system to help promote trauma recovery by means of enhanced extinction learning are potential therapeutic, pharmacological candidates. |
2025-01-31 |
2025-02-02 |
Not clear |
| Hanane Doumar, Hicham El Mostafi, Aboubaker Elhessni, Mohamed Ebn Touhami, Abdelhalem Mesfiou. Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review. IBRO neuroscience reports. vol 18. 2025-01-27. PMID:39866750. |
exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in alzheimer's disease: a review. |
2025-01-27 |
2025-01-29 |
Not clear |